Moderate hyperhomocysteinemia is associated with an increased risk of coronary heart disease (CHD). An inverse relationship usually exists between homocysteine and folate concentrations, and folate supplementation is often able to lower homocysteine concentrations. Thus, insufficient dietary intake of folate and/or vitamin B 12 is considered to be responsible for the development of hyperhomocysteinemia. Inflammation and immune activation appear also to be important in the pathogenesis of CHD and may influence availability of folate. Blood concentrations of homocysteine, Β vitamins and neopterin were examined in 35 patients with CHD verified by coronary angiography, (2 1 patients with one-artery disease, 9 with two-or three-artery disease, 5 with restenosis). Compared to 30 healthy controls, a significant proportion of patients presented with increased homocysteine concentrations. Hyperhomocysteinemia coincided with lower folate and also with higher neopterin concentrations indicating immune system activation. In addition, correlations existed between neopterin and homocysteine (r = 0.472, ρ < 0.01) and folate (r = -0.370, ρ = 0.01). We conclude that higher homocysteine is not only associated with lower circulating folate but also with higher neopterin. Immune activation could be involved to cause an increased demand for folate resulting in hyperhomocysteinemia even when dietary folate intake is within the recommended range.
Introduction
Hyperhomocysteinemia has been established as an independent risk factor for atherosclerosis and other vascular diseases (1, 2) . Homocysteine was proposed to be per se involved in the inflammation process, and increasing homocysteine concentrations in ischemia may lead to leukocyte recruitment in the affected tissue (3) . Homocysteine may promote growth of vascular endothelial and smooth muscle cells (3, 4) . Therefore, hyperhomocysteinemia has been proposed as a link to atherosclerosis development and progression.
Homocysteine, a non-protein-forming amino acid, is formed from S-adenosyl methionine by transmethylation and is remethylated via a vitamin B 12 -and folic acid-dependent reaction to methionine especially in negative methionine balance states. Alternatively homocysteine is added to serine forming cystathionine (a vitamin B 6 -dependent reaction) which in turn is submitted to a transsulfuration process yielding cysteine and a-ketobutyrate. Therefore, insufficient availability of folate and vitamin B 12 is considered to be responsible for the development of hyperomocysteinemia (1, 2) .
Studies have reported an association between neopterin levels and the grade of atherosclerosis (5 -7). Neopterin, a pteridine derivative secreted by monocyte-derived macrophages upon stimulation with the cytokine interferon-γ, is a sensitive marker of cellmediated immune activation (8, 9) . Inflammation and immune activation appear to be important in the pathogenesis of C.HD and may underlie excessive production of reactive oxygen species (10, 11) . Since methvltetrahydrofolate, the biologically active cofactor lor the conversion of homocysteine to methionine, is very susceptible to oxidation, oxidative stress could be crucial to degrade folate resulting in hyperhomocysteinemia (12 To find out a possible relationship between immune activation and the development of hyperhomocysteinemia in CHD, serum concentrations of homocysteine, folate and vitamin B 12 were examined in patients, and data were compared to concentrations of neoptcrin.
Patients and Methods

Patients and controls
Thirty-five patients with CHD verified by coronary angiography at the Paul Stradin's Clinical University Hospital of Riga (9 females, 26 males; age mean ± S.D.: 60.8 ± 9.5 years) were examined in this study which was approved by the local ethics committee and patients gave informed consent to participate. Patients with malignant diseases or clinically relevant gastrointestinal. renal, hepatic, hematological, neurologic or psychiatric diseases as well as patients with metabolic disorders or chronic infections were excluded from the study. Patients were recruited after coronary angiography before percutaneous transluminal coronary angioplasty (PTCA) was performed. In total. 21 patients with o ne-artery disease (including one with diabetes and 6 with renal complications), 9 patients with iwo-(n=7) or three-artery <n=2) disease (three with diabetes and three with diabetes plus renal complications in addition) and 5 with restenosis (ali with renal complications) were included. Patients with renal complications presented with blood urea or creatinine concentrations only slightly above the upper limit of normal. In addition, homocysteine concentrations were measured in serum specimens of 30 healthy controls of similar age (55.2 ± 6.5 years).
Methods
Blood was collected and immediately centrifuged at 4,500 χ g, serum was stored at -20°C until measurements were performed. Homocysteine concentrations were determined by ELISA (Abbott Imx, Chicago, IL), folate and vitamin B 12 were determined by doublelabelled radioimmunoassay (Magic, No Boil, Chiron D ìagnostic corporation, ^Valpole, MA), the active isotopes were ;t I for folate and "Co for vitamin B n .
Neopterin concentrations were measured by ELISA (BRAHMS, Berlin, Germany). All tests were performed according to the manufacturers' instructions.
Statistical analysis Group comparisons were performed by ANOVA and Student's t-test; linear correlation coefficients were calculated. Fisher's exact test was applied for categorical data. P-values below 0.05 were considered to indicate significant differences.
Results
A subgroup of CHD patients presented with increased homocysteine concentrations (mean: 15.0 μιηοΐ/l. Table 1 ), 14 of 35 patients presenting with homocysteine concentrations above 15 pmol/l. the einher defined range of normal (14) . Homocysteine levels in healthy controls of Ihis study (mean ± S.D. 8.9 ± 2.7 umol/i) fit well to the data in the literature, in patients average concentration of folate was 15.6 nmol/i. u! vitamin B, 2 224 pmol/1 and of neopterin 8.51 nmol/l (Table 1 ). Compared to the lower limit of serum vitamin concentrations in healthy subjects (4.0 nmol/l for folate and 150 pmol/1 for vitamin B 12 ; ref. #15) none had decreased folate concentrations, and 7 patients (20%) presented with subnormal vitamin B l2 concentrations. Neopterin concentrations higher than the 95"' Table 2 ). There were no such differences for homocysteine, folate and vitamin B l2 concentrations.
Significant correlation existed between homocyscence on homocysteine concentrations might be low. Homocysteine concentrations correlated inversely with folate levels confirming earlier results of various groups (I, 2). In addition, homocysteine concentrations correlated with neopterin levels. Associations between homocysteine and neopterin concentrations have already been described in patients with abnormal glucose metabolism and with pre-eclampsia (16, 17) , in patients with various forms of neurodegenerative disorders such as Alzheimer's dementia and teine and folate (r = -0.376, ρ = 0.01) and between homocysteine and neopterin concentrations (r = -0.472, ρ < 0.01; Fig.î) . In addition, neopterin concentrations correlated inversely with folate concentrations (r = -0.469, ρ < 0.01; Fig.l) . No such relationships were found for vitamin B 12 .
Discussion
In a significant proportion of patients with CHD increased homocysteine concentrations were found. Homocysteine concentrations seem to be higher than expected in our patients as compared with results in other similar studies. This may be partly due to the use of serum instead of plasma specimens. However, homocysteine concentrations in serum of healthy controls well remained in the generally accepted normal range.
Renal impairment may influence homocysteine concentrations, and a high percentage of our patients presented with renal complications. However, serum creatinine and/or urea concentrations were only slightly increased in those patients so that a possible influParkinsons's disease (18) and also in healthy controls (19) .
Earlier an association between neopterin levels and the grade of atherosclerosis has been reported (5 -7). Neopterin is a product of interferon-g-activated monocyte-derived macrophages and is a sensitive marker for Th-1 type immune response (8) . Increased neopterin concentrations are common in patients with viral infections, malignancy, and autoimmune diseases (8) . Although a correlation does not necessarily confirm a causal relationship, the data of this study would be in line with the assumption that increased homocysteine concentrations are linked to immune activation pathways. This conclusion is also strengthened by the observation that homocysteine accumulates in supernatants of stimulated peripheral blood mononuclear cells (13) . Data indicate that T-cell proliferation and oxidative stress may underlie depletion of B-vitamins and development of moderate hyperhomocysteinemia.
Increased neopterin concentrations developing during cellular immune activation are associated with oxidative stress (20) because activated macrophages produce a record of different reactive species in paral- lcl to neopterin as part of the immunological armament. Also neopterin was found to act pro-oxidative per se by increasing the oxidative potential of reactive oxygen species (20) , and e.g., to support LDL oxidation by peroxynitrite (21) . Overwhelming production of reactive species diminishes the cells' antioxidative capacity, in case of which also the chemical reductant 5,6,7,8-tetrahydrofolate may be affected, in turn leading to higher homocysteine concentrations (12) .
Oxidative stress as a result of immune activation and inflammation is considered to be primary among the events leading to CHD (22) . Immune activation could represent the underlying cause of the appearance of increased homocysteine levels even in situations when folate intake is within the recommended range.
Thus, the data would be also in line with the view that hyperhomocysteinemia is developing as a result of the immunopathogenetic pathways involved in CHD rather than being a primary factor in atherogenesis. Similarly, substitution with folate was able to improve endothelial function in CHD earlier than the decline of homocysteine was observed (23) . This beneficial effect of folate was found to be rather independent of homocysteine lowering. Consequently hyperhomocysteinemia during diseases going along with persistent immunoactivation would result from an increased demand for vitamins like folate.
The underlying stimulus for immune system activation leading to increased concentrations of neopterin and other parameters of immune activation in patients with CHD remains unclear. Immune activation in CHD could be related to an infectious background (24) and also an association was observed between Helicobacter pylori scropositivity and higher ncoptcrin concentrations in healthy people (25) In parallel, hyperhomocysteinemia was found to be associated with seropositivity for Chlamydia pneumoniae in patients with atherosclerosis (26) . More recently higher neopterin concentrations in carotid atherosclerosis were reported to be related to differences in endotoxin handling and innate immune mechanisms via Toll-like receptor 4 polymorphism (27, 28) .
Auto-oxidation of homocysteine, especially when its concentration is high, may yield reactive oxygen species and cysteiny! radicals (29) . Homocysteine may be further linked to pro-inflammatory processes as is evident, e.g., from its capability to modulate tumor necrosis factor alpha-mediated cytotoxicity (30) . Since high homocysteine concentrations are found in ischemic tissue, homocysteine was also proposed as a chemoattractant for leukocytes (3) . Thus, on the one hand hyperhomocysteinerrua may result from oxidative depletion of folate, on the other hand it may further promote oxidative stress. Independent from the underlying cause of folate deficiency, patients will benefit from supplementation with folate.
Neopterin could also be directly involved in the pathogenesis of CHD. An interaction between neopterin formation, the production of reactive oxygen intermediates like superoxide anion and the vasodilator nitric oxide appears plausible (31) . In stimulated human monocyte-derived macrophages, neopterin is produced at the expense of biopterin derivatives (8, 31) . Therefore, due to insufficient supply with necessary cofactor 5,6,7,8-tetrahydrobiopterin. these cells might experience a deficiency to release, nitric oxide (32) . Rather inducible nitric oxide synthase in human monocyte-derived macrophages will produce superoxide anion which is likely to react with nitric oxide to form peroxynitrite (33) . Thus, also nitric oxide produced by other human cells like endothelial cells, under oxidative stress will be oxidized and loose its vasodilatory potential (34) .
In conclusion, in CHD patients there exists a close association between higher homocysteine, lower folate and higher neopterin concentrations, the latter indicating an activated immune system. Immunoactivation in the pathogenesis of CHD could be responsible for increased degradation of folate. Therefore, hyperhomocysteinemia may not be primary in the pathogenesis of CHD, rather it may represent an epiphenomen related to the disease process. Further work has to be done to support the view that folate deficiency and hyperhomocysteinemia are not primary in patients with risk for developing CHD.
